SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Pictured: Skyline of Atlanta
Manufacturing
UCB Investing $2B To Build Manufacturing Facility in Georgia
The Belgian drugmaker plans to hire about 330 people at a facility that will use advanced manufacturing technologies including AI, robotics and automation to meet rising demand for key products. This will be UCB’s first biologics manufacturing facility in the U.S.
March 25, 2026
 · 
2 min read
 · 
Nick Paul Taylor
The skyline of New York City
Job Trends
11 Companies Hiring Now in New York
Looking for a biopharma job in New York? Check out the BioSpace list of 11 companies hiring life sciences professionals like you.
March 25, 2026
 · 
2 min read
 · 
Angela Gabriel
Big fish eats small, takeover of the company. Art collage.
Mergers & acquisitions
Merck To Buy Terns, ‘Unprecedented’ Leukemia Drug for $6.7B as Keytruda Cliff Looms
Merck’s acquisition of Terns Pharmaceuticals follows other big-ticket purchases, including of Verona Pharma and Cidara Therapeutics, as the pharma prepares for the impending expiration of its blockbuster’s patents.
March 25, 2026
 · 
3 min read
 · 
Tristan Manalac
Abstract creative art collage, market declines in the stock market. The concept of collapse or bankruptcy.
Cancer
Karyopharm Slides as Mixed Myelofibrosis Results Cloud Regulatory Road
Missing one of its co-primary endpoints could make it difficult for Karyopharm Therapeutics to score conventional approval for Xpovio in myelofibrosis, according to Jefferies analysts.
March 25, 2026
 · 
2 min read
 · 
Tristan Manalac
Espionage in China concept, 3D rendering isolated on white background
Funding
RA Capital Looks to China for Next Startup To Put on SPAC Track to Nasdaq
While RA Capital Management has yet to commit to a merger plan, it noted that its new blank-check company, Research Alliance III, could target companies abroad, including those from China.
March 25, 2026
 · 
2 min read
 · 
Tristan Manalac
Podcast
Gilead’s Ouro Buy, J&J/Protagonist’s Approval, Aurinia’s Revamp, ACIP Confusion, More
Gilead continues its dealmaking spree in the sizzling hot space of I&I as Johnson & Johnson, along with partner Protagonist, notched an FDA approval for a new psoriasis drug. Plus, Aurinia Pharmaceuticals gets a new C-suite, FDA releases draft guidance on non-animal models and the CDC’s vaccine advisory committee is not being disbanded after all.
March 25, 2026
 · 
1 min read
 · 
Heather McKenzie
Grab the amazing business flat stickers icons. This pack contains 50 icons depicting business analysis concepts. It had charts and graphs of different kinds. This pack is in the flat stickers style.
Clinical research
Pharma R&D Spend Drops 3.6% as Pipeline Prioritizations Take Shape
Overall, the top 16 largest pharmaceutical companies spent $159 billion on research and development in 2025, compared to $165 billion the year prior. Here’s where all that cash went at companies like Johnson & Johnson, Amgen and Pfizer.
March 25, 2026
 · 
2 min read
 · 
Annalee Armstrong
Solution Concept with Handshake on Chalkboard Background
NextGen
Trace Unites ALS Teams Behind a Target That Could Broaden Treatment Access
Trace Neuroscience, a member of BioSpace’s NextGen Class of 2026, has learned from the success of Biogen’s Qalsody and aims to bring more treatment options to the ALS community.
March 25, 2026
 · 
3 min read
 · 
Annalee Armstrong
Adults hand drawing pathway for baby boy. Parent influence on child development and future. Parental control and support for growth and education of kid. vector
FDA
Rezolute Lauds ‘Unusual’ FDA Feedback Supportive of Path Forward for Hypoglycemia Drug
While ersodetug missed the Phase 3 primary endpoint of a reduction in hypoglycemia events, Rezolute argued that this goal was confounded in part by behavioral factors. The FDA acknowledged the validity of this argument.
March 24, 2026
 · 
3 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS